GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
39.01
+1.37 (3.64%)
At close: Apr 3, 2025, 4:00 PM
38.50
-0.51 (-1.31%)
After-hours: Apr 3, 2025, 8:00 PM EDT
GSK Revenue
In the year 2024, GSK had annual revenue of 31.38B GBP with 3.46% growth. GSK had revenue of 8.12B in the quarter ending December 31, 2024, with 0.81% growth.
Revenue (ttm)
31.38B GBP
Revenue Growth
+3.46%
P/S Ratio
1.99
Revenue / Employee
457,183 GBP
Employees
68,629
Market Cap
78.18B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
GSK News
- 7 hours ago - GSK resolves patent lawsuit against Pfizer over RSV vaccines - Reuters
- 10 hours ago - New Study Shows Shingles Vaccine Linked To 20% Lower Dementia Risk, GSK Stock Pops - Benzinga
- 1 day ago - Pharma stocks survive market rout on tariff exemption, but uncertainty continues - Reuters
- 7 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in GSK plc Lawsuit - GSK - PRNewsWire
- 9 days ago - Blujepa (gepotidacin) Approved by US FDA for Treatment of Uncomplicated Urinary Tract Infections (uUTIs) in Female Adults and Pediatric Patients 12 Years of Age and Older - Business Wire
- 9 days ago - US FDA approves GSK's urinary tract infection drug - Reuters
- 9 days ago - GSK studying if best-selling shingles vaccine lowers dementia risk - Reuters
- 10 days ago - GSK says European regulator reviewing expanded use of asthma drug Nucala - Reuters